Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

@article{Wolpin2009OralMI,
  title={Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.},
  author={Brian Wolpin and Aram F. Hezel and Thomas Adam Abrams and Lawrence Scott Blaszkowsky and Jeffrey A. Meyerhardt and Jennifer A W Chan and Peter C. Enzinger and Brittany A Allen and Jeffrey T. Clark and David P. Ryan and Charles S. Fuchs},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 2},
  pages={193-8}
}
PURPOSE The PI3K/Akt/mTOR pathway is activated in the majority of pancreatic cancers, and inhibition of this pathway has antitumor effects in preclinical studies. We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine. PATIENTS AND METHODS Thirty-three patients with gemcitabine-refractory, metastatic pancreatic cancer were treated continuously with… CONTINUE READING